1ZP2MA, also known as [1-(indolizin-1-yl)propan-2-yl](methyl)amine or as 1-(indolizin-1-yl)-N-methylpropan-2-amine, is a monoamine releasing agent and an indolizine derivative.[1] It is the analogue and positional isomer of the stimulant-like drug α,N-dimethyltryptamine (α,N-DMT or N-methyl-α-methyltryptamine (N-methyl-αMT)) in which the indole ring has been replaced with an indolizine ring.[1] 1ZP2MA has been found to be a potent dopamine releasing agent, with an EC50 of 62 nM.[1] It is the α-methyl and N-desmethyl analogue of (2-(indolizin-1-yl)ethyl)dimethylamine (TACT908; the indolizine analogue of dimethyltryptamine (DMT)).[1] 1ZP2MA and 2ZEDMA were patented by Tactogen in 2023.[1]

See also

References

  1. ^ a b c d e WO patent 2023183613A2, Baggott MJ, "Indolizine compounds for the treatment of mental disorders or inflammation", published 2023 September 28, assigned to Tactogen 


Allikas: https://en.wikipedia.org/wiki/1ZP2MA
No tags for this post.